Inlyta

Covered Uses:	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria:	Combination use with other tyrosine kinase inhibitors such as sorafenib, sunitinib
Required Medical Information:	For RCC coverage is provided after failure with one prior systemic therapy
Age Restrictions:
Prescriber Restrictions:
Coverage Duration:	12 months
Other Criteria:

Last Modified on 12/19/2012